Dr. Hamdi Abdelazim
Chairman of Kasr Al-Ainy School Of Oncology (KASO), official Cancer education organization, Department of Oncology, Faculty of Medicine, Cairo University.
Professor of Clinical Oncology, Faculty of Medicine, Cairo University, Cairo, Egypt
President of Africa Middle East Cancer Research Inter group.
Referee for the Annals of Oncology Journal, THE BREAST, The Breast Journal (TBJ), BMC Cancer, Chemotherapy journal , Advances in Cancer Research & Treatment , Journal of the Egyptian National Cancer Institute, and the Chinese Clinical Oncology Journal.
Friday 3-5-2024 Day 1
Advanced HER2-positive/HER2-low breast cancer
Patient with brain metastasis and stable extracranial disease: when to change antiHER2-based therapy
Patient with active brain metastasis: locoregional therapy vs systemic therapy
Patient with active brain metastasis: T-DXd vs.
tucatinib-based therapy
Can we use TDM1 after T-DXd
Role of repeated biopsies to guide ADCs in HER2-low BC
Moderator: 
Shereef Elsamany
Panel:
Friday 3-5-2024 Day 1
Genomic tools in breast cancer
- chemotherapy in high risk lobular/mucinous BC?
- Neoadjuvant therapy in premenopausal patients with lobular BC?
Adjuvant therapy with node negative and node positive lobular BC?
Adjuvant therapy in luminal BC with RS 16-25?
Can genomic tools guide adjuvant cdk4-6 inhibitors in N0/N1 tumours?? - Oncotype DX and selection of neoadjuvant hormonal vs chemotherapy therapy
- Role of interval Ki67 assessment with neoadjuvant hormonal therapy
Moderator: 
Ahmed Alshehri
Panel:
